Kringle Pharma
Kringle Pharma is a late clinical-stage biopharmaceutical company dedicated to developing regenerative medicines based on HGF (Hepatocyte Growth Factor) protein. Their mission is to bring breakthrough HGF protein-based therapies to patients suffering from intractable and mainly rare diseases. The company leverages its expertise in manufacturing pharmaceutical-grade HGF protein to advance therapeutic drug development for conditions with significant unmet medical needs.
Industries
Nr. of Employees
small (1-50)
Kringle Pharma is currently seeking investment
Kringle Pharma is seeking a growth-stage investment in the range of
Products
Recombinant human HGF protein therapeutic candidates
Recombinant human hepatocyte growth factor (HGF) protein candidates developed as regenerative therapeutics and progressed into clinical trials for intractable and primarily rare diseases, including acute spinal cord injury.
Recombinant human HGF protein therapeutic candidates
Recombinant human hepatocyte growth factor (HGF) protein candidates developed as regenerative therapeutics and progressed into clinical trials for intractable and primarily rare diseases, including acute spinal cord injury.
Expertise Areas
- Regenerative medicine
- Recombinant protein therapeutics
- Clinical trial management for rare and intractable diseases
- Biologics manufacturing and CMC
Key Technologies
- Recombinant protein production
- Protein purification and analytical characterization
- Regenerative biologic modalities
- Clinical development methodologies for biologics
Key People
Kazunori Maebashi
Director, Pharmaceutical Department
Matthew Vogelhuber, R.Ph.
President and US Head of Operations
Kazunori Maebashi
Director, Pharmaceutical Department
Matthew Vogelhuber, R.Ph.
President and US Head of Operations
Investors
Maruishi Pharmaceutical Co. Ltd.
$3,773,663 funded.
Announced on 2020-08-31.
Venture Round - Kringle Pharma
$6,824,742 funded.
Announced on 2020-04-04.
Series C - Kringle Pharma
Announced on 2020-03-02.
Venture Round - Kringle Pharma
$8,789,376 funded.
Announced on 2020-02-28.
Tohoku University Venture Partners
$1,788,378 funded.
Announced on 2018-07-31.
DBJ Capital, Keio Innovation Initiative
$5,360,451 funded.
Announced on 2016-12-05.
Maruishi Pharmaceutical Co. Ltd.
$3,773,663 funded.
Announced on 2020-08-31.
Venture Round - Kringle Pharma
$6,824,742 funded.
Announced on 2020-04-04.
Series C - Kringle Pharma
Announced on 2020-03-02.
Venture Round - Kringle Pharma
$8,789,376 funded.
Announced on 2020-02-28.
Tohoku University Venture Partners
$1,788,378 funded.
Announced on 2018-07-31.
DBJ Capital, Keio Innovation Initiative
$5,360,451 funded.
Announced on 2016-12-05.
News & Updates
Kringle Pharma's recombinant human HGF, KP-100IT, received Orphan Drug Designation from the U.S. FDA for the treatment of acute spinal cord injury.
An analyst report on Kringle Pharma was released by Shared Research Inc.
Kringle Pharma released its financial results for the nine months ended June 30, 2025, under Japanese GAAP (Non-consolidated).
An analyst report on Kringle Pharma was released by Shared Research Inc.
The U.S. FDA granted Orphan Drug Designation to Kringle Pharma's recombinant human HGF, KP-100IT, for the treatment of acute spinal cord injury.
Kringle Pharma's recombinant human HGF, KP-100IT, received Orphan Drug Designation from the U.S. FDA for the treatment of acute spinal cord injury.
An analyst report on Kringle Pharma was released by Shared Research Inc.
Kringle Pharma released its financial results for the nine months ended June 30, 2025, under Japanese GAAP (Non-consolidated).
An analyst report on Kringle Pharma was released by Shared Research Inc.
The U.S. FDA granted Orphan Drug Designation to Kringle Pharma's recombinant human HGF, KP-100IT, for the treatment of acute spinal cord injury.